Beacon Biosignals

Executive Summary

Beacon Biosignals is an AI-driven neurotechnology company headquartered in Boston, MA, founded in 2019. The company is dedicated to advancing brain health by combining quantitative sleep EEG analysis with proprietary artificial intelligence algorithms. Its platform is designed to identify novel biomarkers and accelerate drug development for neurological and psychiatric conditions. Beacon’s end-to-end solution integrates an FDA-cleared at-home EEG headband with a cloud-based analytics platform, enabling objective, scalable endpoints for clinical trials. By focusing on sleep-based EEG biomarkers, the company addresses a critical unmet need in CNS drug development, where traditional subjective measures often fail to capture treatment effects reliably. Beacon’s technology holds the potential to transform how neurological and psychiatric diseases are diagnosed and monitored, and to significantly de-risk clinical trials by providing more sensitive and objective outcome measures. The company targets a large market opportunity, as CNS disorders represent a substantial burden globally and drug development in this space suffers from high failure rates. With its FDA-cleared device and AI analytics, Beacon is well-positioned to partner with pharmaceutical companies and research institutions. However, as a private company without disclosed financials, its valuation and revenue remain speculative. The competitive landscape includes other digital biomarkers and EEG analytics firms, but Beacon’s integrated hardware-software approach and sleep focus offer differentiation.

Upcoming Catalysts (preview)

• Q3 2026FDA clearance for expanded sleep biomarker algorithm75% success
• Q4 2026Major pharmaceutical partnership for clinical trial deployment65% success
• Q2 2026Series B funding round completion80% success